AGAlicja Gawlik

Alicja Gawlik

*This is an algorithmically generated author record based on publicly available information.

Alicja Gawlik has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AI IN PSYCHIATRIC DIAGNOSTICS – A REVIEW

    by Wiktor Rybicki, Radosław Dutczak, Aleksandra Sobieska, Patrycja Mularczyk, Julia Jaguszewska, Weronika Martyna Górska, Mateusz Okoń, Alicja Gawlik, Alicja Korpacka, Iga Maria Owczarek-Danowska, et al.

    Introduction: Artificial intelligence (AI) is increasingly being used in psychiatry, with side effects on solutions stemming from the subjectivity of diagnosis, limited care, and biological complexity, which is subject to threats. Mental disorders affect 293 million people worldwide and pose a burden on human health [9]. Aim: The aim of this review is to summarize the current state of knowledge on AI applications in psychiatric diagnostics, with specific focus on: (1) analysis of communication traffic of AI algorithms, (2) analysis of the results of AI-based primary control, (3) extension of methodological and ethical implications, and (4) extension of research. Methods: A review of the research literature was conducted in the field of Basic Language Processing (NLP) in digital phenotyping, AI-assisted neuroimaging, and the ethical and legal implications of implementing these technologies. Meta-analyses, specific reviews, and original empirical studies completed between 2015 and 2026 were analyzed. Results: A meta-analysis reported a cumulative AI diagnostic accuracy of 85% and a therapeutic efficacy of 84% in specific applications [8]. NLP enabled independent assessment, achieving an 86% (AUC 0.93) in studies on psychosis risk states [18]. Chatbots (Woebot, Wysa, Youper) demonstrate the consequences of problem occurrence and anxiety [9]. A review of 555 neuroimaging models revealed that 83.1% of the symptoms appear as a consequence rather than being triggered by a utility [32]. The most important ethical concerns were identified, including algorithm opacity ("black box"), liability, and data privacy [54, 56, 61]. Conclusions: AI in psychiatric diagnostics has demonstrated transformative potential, particularly in the areas of NLP and digital phenotyping, but current neuroimaging models require methodological improvements. The development of comprehensive ethical frameworks and extensions, simple algorithms, and model validation in large, population-based cohorts are essential. The ultimate success of AI in psychiatry will depend on striking a balance between technological innovation and respect for fundamental ethical values, while maintaining a paramount clinical role in diagnostic and therapeutic procedures.

  • Open Access

    APPLICATIONS OF VIRTUAL REALITY TECHNOLOGY IN PSYCHIATRY – A REVIEW

    by Wiktor Rybicki, Radosław Dutczak, Aleksandra Sobieska, Alicja Korpacka, Patrycja Mularczyk, Mateusz Okoń, Zuzanna Lecyk, Alicja Gawlik, Małgorzata Lubowiecka

    Virtual reality (VR) is a promising tool supporting diagnostics and therapy in psychiatry, aligning with the Health 4.0 paradigm of personalized healthcare. This review synthesizes the available scientific evidence on VR applications in psychiatry, with particular emphasis on therapeutic mechanisms, clinical effectiveness, and identification of research gaps. The strongest empirical evidence concerns VR exposure therapy (VRET) in the treatment of anxiety disorders, where the effectiveness of VRET is comparable to in vivo exposure (Suso-Ribera et al., 2019). In the case of post-traumatic stress disorder, graded exposure based on the patient's responses has been shown to be a key moderator of effectiveness, yielding significant therapeutic effects (Heo and Park, 2022). In psychotic disorders, automated VR interventions reduce agoraphobic avoidance (Freeman et al., 2022), while in social phobia, optimal results are achieved by combining VRET with cognitive-behavioral interventions (Tan et al., 2025). The neurobiological mechanisms of therapeutic change are based on amygdala activation and modulation of the medial prefrontal cortex and hippocampus, enabling extinction of the fear response. However, generalization of learned responses beyond the virtual context remains a key challenge (Freeman, 2017). Personalization of interventions using artificial intelligence is in the early stages of development (Bergsnev and Sánchez Laws, 2026). From a clinical perspective, VR is characterized by high acceptability and low dropout rates. Further development of the field requires comparative studies with active interventions, standardization of the sense of presence measurement, and validation of tools for measuring social attitudes toward VR therapy. Integrating VR with traditional therapeutic methods, rather than replacing them, seems to be the most justifiable path forward for this field.